ALX Oncology Holdings Inc. (ALXO) Stock Grade

About ALX Oncology Holdings Inc.'s fundamentals

ALX Oncology is a biotechnology company with a market capitalization of $187.0 million that is currently unprofitable, having reported a net loss in its latest annual statement. The company generated no revenue growth year-over-year and maintains a net margin of 0.0%, reflecting its pre-commercial or early-stage revenue phase. As a biotech firm without positive earnings, traditional valuation metrics like P/E ratio and return on equity are not applicable. The company does not pay a dividend, which is typical for early-stage biotechnology companies focused on research and development.